Universe Pharmaceuticals (UPC) Liabilities and Shareholders Equity (2020 - 2026)

Universe Pharmaceuticals has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $71.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $71.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.1 billion (changed N/A YoY) and the FY2025 annual result came in at $69.3 million, down 99.9% from the prior year.
• Liabilities and Shareholders Equity rose to $71.5 million in Q1 2026 per UPC's latest filing, from $69.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $68.0 billion in Q3 2024 and troughed at $41.7 million in Q3 2023.
• A 5-year average of $8.5 billion and a median of $69.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity jumped 162762.16% in 2024, then slumped 99.9% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $59.5 million in 2022, then retreated by 29.92% to $41.7 million in 2023, then surged by 162762.16% to $68.0 billion in 2024, then plunged by 99.9% to $69.3 million in 2025, then increased by 3.12% to $71.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $71.5 million, $69.3 million, and $68.0 billion for Q1 2026, Q3 2025, and Q3 2024 respectively.